Semaglutide and Protein Intake: How Much and Why
At a glance
- Protein target on the label / None; Wegovy says reduced-calorie diet plus more physical activity [1]
- Ozempic diet instruction / Adjunct to diet and exercise; no weight-loss indication [2]
- Nausea, Wegovy 2.4 mg / 44% vs 16% on placebo [1]
- Diarrhea, vomiting, constipation / 30% vs 16%, 24% vs 6%, 24% vs 11% [1]
- Decreased appetite, tablets / 6% on 7 mg, 9% on 14 mg vs 1% [3]
- STEP 1 weight change / -14.9% vs -2.4% at 68 weeks [4]
What the labels say about diet
The Wegovy indication is written for use with a reduced-calorie diet and more physical activity, and that is the whole of the diet instruction in the indication [1]. Ozempic is an adjunct to diet and exercise for glycemic control, cardiovascular risk reduction and kidney outcomes in type 2 diabetes [2]. Neither indication names a protein target or a gram figure for any macronutrient [1][2]. Ozempic has no weight-loss indication; that indication belongs to Wegovy [2][1].
Appetite, gastric emptying and GI reactions
Semaglutide binds and activates the GLP-1 receptor, including receptors in brain areas that regulate appetite and calorie intake, and it delays gastric emptying [1].
In pooled placebo-controlled Wegovy trials of 2.4 mg weekly in adults with obesity or overweight, up to 68 weeks (2,116 on Wegovy, 1,261 on placebo), nausea occurred in 44% vs 16%, diarrhea in 30% vs 16%, vomiting in 24% vs 6%, constipation in 24% vs 11% and abdominal pain in 20% vs 10%. Any GI reaction was 73% vs 47%, and 6.8% vs 3.2% stopped treatment for an adverse reaction [1]. The Ozempic label says that most reports of nausea, vomiting and diarrhea occurred during dose escalation [2]. On the tablets, reduced appetite is itself listed as an adverse reaction, at 6% on 7 mg and 9% on 14 mg versus 1% on placebo [3].
What the weight-loss trials measured
STEP 1 enrolled 1,961 adults with a BMI of 30 or higher (27 or higher with a weight-related condition) and no diabetes, randomized 2:1 to semaglutide 2.4 mg weekly or placebo for 68 weeks with lifestyle intervention. Mean weight change was -14.9% versus -2.4%, and 86.4% versus 31.5% lost at least 5% [4]. Those figures are changes in total body weight.
Oral tablets and food timing
Ozempic injection has no food timing rule; it is given once weekly at any time of day, with or without meals [2]. For oral semaglutide tablets, the label specifies an empty stomach, up to 4 ounces of plain water, swallowing the tablet whole, and waiting at least 30 minutes before food, drinks or other oral medicines [1][3].
Frequently asked questions
Does semaglutide make it harder to eat enough protein?
What diet does the Wegovy label describe?
Can I take oral semaglutide with a protein shake?
How much weight did people lose in the main trial?
References
- U.S. National Library of Medicine, DailyMed. Wegovy injection and Wegovy tablets (Novo Nordisk) prescribing information. Wegovy injection and Wegovy tablets (Novo Nordisk) label
- U.S. National Library of Medicine, DailyMed. Ozempic injection (Novo Nordisk) prescribing information. Ozempic injection (Novo Nordisk) label
- U.S. National Library of Medicine, DailyMed. Rybelsus and Ozempic tablets (Novo Nordisk) (oral semaglutide) prescribing information. Rybelsus and Ozempic tablets (Novo Nordisk) (oral semaglutide) label
- Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Once-Weekly Semaglutide in Adults with Overweight or Obesity